New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination

Takaaki Shigematsu; Yu Yamaguchi; Takeo Watanabe; Kazutaka Tsujimoto; Fuminori Sato; Tetsuya Yamada; Motoyoshi Tsujino

doi:10.2169/internalmedicine.5053-24

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination

Takaaki Shigematsu, Yu Yamaguchi, Takeo Watanabe, Kazutaka Tsujimoto, Fuminori Sato, Tetsuya Yamada, Motoyoshi Tsujino

著者情報

キーワード: Fulminant type 1 diabetes mellitus, COVID-19 RNA vaccine, pancreatic enlargement, autoimmune disease

ジャーナルオープンアクセス早期公開

論文ID: 5053-24

DOI https://doi.org/10.2169/internalmedicine.5053-24

この記事には本公開記事があります。

The final version of this article is now available: Vol. 64 (2025), No. 11 pp. 1691-1695

詳細

抄録

A 31-year-old Japanese man was admitted with a slight fever and epigastric pain. He had received his third Moderna COVID-19 vaccine dose (Spikevax, mRNA-1273) 16 days before his visit. His serum amylase level was elevated, and computed tomography (CT) found pancreatic enlargement. Acute pancreatitis was diagnosed, and the patient was treated with fasting and intravenous fluids. However, on day 3 of hospitalization, his blood glucose level had increased to 320 mg/dL. His serum and urinary C-peptide were remarkably low (≤0.03 ng/mL and ≤0.6 μg/day, respectively) Finally, fulminant type 1 diabetes mellitus caused by the COVID-19 mRNA vaccine was diagnosed.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）